NDAORALTABLET, DELAYED RELEASE
Approved
Dec 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
OMEPRAZOLE (omeprazole) by Bridge Therapeutics is proton pump inhibitors [moa]. First approved in 2007.
Drug data last refreshed 5m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Omeprazole is a proton pump inhibitor (PPI) available as an oral delayed-release tablet that reduces gastric acid secretion by inhibiting the H+/K+-ATPase enzyme in parietal cells. It is used to treat acid-reflux disorders, peptic ulcer disease, and gastroesophageal reflux disease (GERD). This is a generic formulation marketed by Bridge Therapeutics in a mature, highly competitive segment.
LOE Approaching
Product is in late lifecycle stage with high competitive pressure (30/100), suggesting a defensive commercial posture and smaller team focus on retention and cost management rather than growth initiatives.
Mechanism of Action
Proton Pump Inhibitors
Pharmacologic Class:
Proton Pump Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Started Oct 2025
28 enrolled
Healthy Adult Participants
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
Started Sep 2025
22 enrolled
Healthy Volunteer
Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal
Started Sep 2025
4 enrolled
Digestive HealthGastrointestinal Health
A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants
Started May 2025
36 enrolled
Healthy
Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
Started May 2025
24 enrolled
Pharmacokinetic ProfilesY-3 for InjectionDrug-drug Interaction+4 more
Worked on OMEPRAZOLE at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.